From the Food and Drug Administration.
Nightingale
S L
SL
Office of Health Affairs, FDA, Rockville, MD 20857.
D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D017277:Drug Approval; D004827:Epilepsy / Q000188:drug therapy*; D000078328:Felbamate; D006495:Heparin, Low-Molecular-Weight / Q000592:standards / Q000627:therapeutic use*; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D048448:Phenylcarbamates; D011409:Propylene Glycols / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000927:Anticonvulsants; D006495:Heparin, Low-Molecular-Weight; D048448:Phenylcarbamates; D011409:Propylene Glycols; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000078328:Felbamate; D000068556:Interferon beta-1a